The introduction of Retatrutide ZPHC, at a dosage of 120mg, is creating considerable buzz within the healthcare community. This innovative dual GIP and GLP-1 target medication seems to offer impressive improvements in body loss compared to previous therapies. Early clinical studies have indicated